Compare Expensify Inc (EXFY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Expensify Inc trades at $2.3 (market cap $208.82M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 610.8× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EXFY | VRTX | |
|---|---|---|
Market Cap | $208.82M | $127.55B |
Volume | 456,102 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $2.72 | $557.96 |
52-Week Low | $0.75 | $407.37 |
Typical Hold Time | 41 Days | 120 Days |
Enterprise Value | $148.44M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.27, up 1.79% with a neutral technical signal. The company shows mixed fundamentals with revenue stabilizing around $140M but persistent net losses. Recent quarters show earnings improvement with two beats, while analyst consensus is bullish with a $13.75 price target. Business developments include AI integrations and European expansion of corporate card offerings.
The outlook remains speculative given negative profitability metrics, though cash flow improvements and strategic partnerships provide potential catalysts. Key risks include competitive pressure in expense management and the challenge of achieving sustainable profitability. The significant gap between current price and analyst targets suggests upside potential if execution improves.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
